Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections

Yarmus, Lonny; Nguyen, Phan; Montemayor, Kristina; Jennings, Mark T.; Bade, Brett C.; Shafiq, Mājid; Silvestri, Gerard A.; Steinfort, Daniel P.

doi:10.1111/resp.13306

Cited by 3 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is one of the most common cancers leading to cancer-related death worldwide (1). In US, 224,210 new cases of lung cancer are estimated for the year 2014 with 159,260 estimated deaths (2).…”

Section: Introductionmentioning

confidence: 99%

Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients

Jiang

Shi

Yuan

et al. 2018

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Elevated bilirubin has been associated with protection of cardiovascular and kidney systems, whereas decreased bilirubin may predispose respiratory diseases. However, whether serum bilirubin levels are associated with lung cancer remains unclear. Here, clinical and pathologic data of a cohort of 363 lung cancer patients along with 363 age-and gender-matched healthy subjects were collected. The association of serum bilirubin levels with lung cancer was analyzed. The levels of serum bilirubin were significantly lower in lung cancer patients. The aspartate transaminase and alkaline phosphatase levels were significantly higher in lung cancer. Multi-classification logistics regression analysis revealed low total bilirubin level [OR (95%CI), 1.12 (1.02-1.23)], aspartate transaminase [OR (95%CI), 1.12 (1.02-1.23)], and alanine transaminase [OR (95%CI), 1.12 (1.02-1.23)] were risk factors in lung cancer. Serum bilirubin levels were significantly changed among small cell lung cancer (SCLC), lung adenocarcinoma (LAC) and lung squamous cell carcinoma (LSC). Total bilirubin level, smoke history and heart disease were risk factors for subtypes. Compared with LSC, patients with smoke history had significant higher risk in LAC [OR (95% Confidence Interval, CI), 4. 49 (1.70, 11.96)]. Compared with LSC, patients with smoke history [OR (95%CI), 4.49 (1.70, 11.96)] and heart disease [OR (95%CI), 4.49 (1.70, 11.96)] had significant higher risk in SCLC. Compared with SCLC, patients with low total bilirubin [OR (95%CI), 1.12 (1.02-1.23)] and heart disease [OR (95%CI), 3.52(1.01-12.23)] had significant higher risk in LAC. Taken together, these results suggested low serum bilirubin levels are tightly associated with lung cancer, especially with LAC. Serum bilirubin levels might serve as a predictor for lung cancer patients clinically.

show abstract

Section: Introductionmentioning

confidence: 99%

Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients

Jiang

Shi

Yuan

et al. 2018

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…Lung cancer is one of the most common malignant tumors with high incidence of mortality in the world (1). In the last 50 years, the incidence of lung cancer has significantly increased, and the disease is more common in males than in females (2,3).…”

Section: Introductionmentioning

confidence: 99%

Esculetin inhibits the proliferation of human lung cancer cells by targeting epithelial-to-mesenchymal transition of the cells

Wang

et al. 2019

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Lung cancer is characterized by high mortality and it is a serious threat to human health. At present, strategies used for treatment of lung cancer are not effective. Hence, there is need for new drugs that can effectively treat the metastatic stage of the cancer. The present study investigated the effect of esculetin on proliferation and epithelial-mesenchymal transition (EMT) of human lung cancer (A549) cells, and the underlying mechanism.Cell proliferation was assessed using MTT assay. Real-time quantitative polymerase chain reaction (qRT-PCR) and Western blotting were employed for the determination of changes in the expression levels of vimentin, Snail and E-cadherin mRNAs. Cell invasion and migration were determined using Transwell assay. The results showed that esculetin significantly and time-and dose-dependently inhibited the proliferation of A549 cells (p < 0.05). It also significantly and dose-dependently reduced their invasive ability (p < 0.05). The levels of expression of vimentin and Snail mRNAs were significantly and dose-dependently down-regulated in esculetin-treated A549 cells, when compared with the control cells (p < 0.05). Esculetin treatment significantly and dose-dependently upregulated the expression of E-cadherin mRNA (p < 0.05).These results demonstrate that esculetin effectively inhibits the proliferation of A549 cells, and regulates EMT of the cells via the down-regulation of vimentin and Snail, and up-regulation of E-cadherin expressions.

show abstract

The Research Progress of Traditional Chinese Medicine Compound Control MAPK Signaling Pathways for the Treatment of Lung Cancer

霍

2023

TCM

View full text Add to dashboard Cite

Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections

Cited by 3 publications

References 60 publications

Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients

Levels of serum bilirubin in small cell lung cancer and non-small cell lung cancer patients

Esculetin inhibits the proliferation of human lung cancer cells by targeting epithelial-to-mesenchymal transition of the cells

The Research Progress of Traditional Chinese Medicine Compound Control MAPK Signaling Pathways for the Treatment of Lung Cancer

Contact Info

Product

Resources

About